Outcomes of elderly patients with organophosphate intoxication

Sci Rep. 2021 Jun 2;11(1):11615. doi: 10.1038/s41598-021-91230-2.

Abstract

This study analysed the clinical patterns and outcomes of elderly patients with organophosphate intoxication. A total of 71 elderly patients with organophosphate poisoning were seen between 2008 and 2017. Patients were stratified into two subgroups: survivors (n = 57) or nonsurvivors (n = 14). Chlorpyrifos accounted for 33.8% of the cases, followed by methamidophos (12.7%) and mevinphos (11.3%). Mood, adjustment and psychotic disorder were noted in 39.4%, 33.8% and 2.8% of patients, respectively. All patients were treated with atropine and pralidoxime therapies. Acute cholinergic crisis developed in all cases (100.0%). The complications included respiratory failure (52.1%), aspiration pneumonia (50.7%), acute kidney injury (43.7%), severe consciousness disturbance (25.4%), shock (14.1%) and seizures (4.2%). Some patients also developed intermediate syndrome (15.5%) and delayed neuropathy (4.2%). The nonsurvivors suffered higher rates of hypotension (P < 0.001), shock (P < 0.001) and kidney injury (P = 0.001) than survivors did. Kaplan-Meier analysis indicated that patients with shock suffered lower cumulative survival than did patients without shock (log-rank test, P < 0.001). In a multivariate-Cox-regression model, shock was a significant predictor of mortality after intoxication (odds ratio 18.182, 95% confidence interval 2.045-166.667, P = 0.009). The mortality rate was 19.7%. Acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 15.5%, and 4.2% of patients, respectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / drug therapy*
  • Acute Kidney Injury / mortality
  • Acute Kidney Injury / physiopathology
  • Affect / drug effects
  • Aged
  • Antidotes / therapeutic use*
  • Atropine / therapeutic use
  • Chlorpyrifos / antagonists & inhibitors
  • Chlorpyrifos / toxicity
  • Female
  • Humans
  • Insecticides / antagonists & inhibitors
  • Insecticides / toxicity*
  • Male
  • Mevinphos / antagonists & inhibitors
  • Mevinphos / toxicity
  • Middle Aged
  • Organophosphate Poisoning / drug therapy*
  • Organophosphate Poisoning / etiology
  • Organophosphate Poisoning / mortality
  • Organophosphate Poisoning / physiopathology
  • Organothiophosphorus Compounds / antagonists & inhibitors
  • Organothiophosphorus Compounds / toxicity
  • Pneumonia, Aspiration / chemically induced
  • Pneumonia, Aspiration / drug therapy*
  • Pneumonia, Aspiration / mortality
  • Pneumonia, Aspiration / physiopathology
  • Pralidoxime Compounds / therapeutic use
  • Psychotic Disorders / drug therapy
  • Psychotic Disorders / etiology
  • Psychotic Disorders / mortality
  • Psychotic Disorders / physiopathology
  • Respiratory Insufficiency / chemically induced
  • Respiratory Insufficiency / drug therapy*
  • Respiratory Insufficiency / mortality
  • Respiratory Insufficiency / physiopathology
  • Retrospective Studies
  • Seizures / chemically induced
  • Seizures / drug therapy
  • Seizures / mortality
  • Seizures / physiopathology
  • Shock / chemically induced
  • Shock / drug therapy
  • Shock / mortality
  • Shock / physiopathology
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antidotes
  • Insecticides
  • Organothiophosphorus Compounds
  • Pralidoxime Compounds
  • Mevinphos
  • Atropine
  • methamidophos
  • Chlorpyrifos
  • pralidoxime